PreveCeutical Medical Inc.
PRVCF
$0.025
-$0.0005-1.96%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 847.10K | 482.10K | 629.70K | 561.20K | 488.50K |
| Depreciation & Amortization | 7.70K | 7.40K | 7.40K | 7.30K | 7.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 915.10K | 549.70K | 699.80K | 637.10K | 564.50K |
| Operating Income | -915.10K | -549.70K | -699.80K | -637.10K | -564.50K |
| Income Before Tax | -1.22M | -857.90K | -996.30K | -928.80K | -835.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.22 | -0.86 | -1.00 | -0.93 | -0.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.22M | -857.90K | -996.30K | -928.80K | -835.90K |
| EBIT | -915.10K | -549.70K | -699.80K | -637.10K | -564.50K |
| EBITDA | -907.30K | -542.30K | -692.50K | -629.90K | -557.20K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 2.15B | 2.15B | 2.14B | 2.14B | 2.14B |
| Average Diluted Shares Outstanding | 2.15B | 2.15B | 2.14B | 2.14B | 2.14B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |